patient with a severe uncomplicated pernicious anemia). Such patients may show an "optimal" reticulocyte response and "optimal" or almost "optimal" red cell response to single injections of 100 to 200 pg. of vitamin B12. But megaloblastic change reappears in the marrows of these patients while their serum B12 concentrations are still within the normal range. If these patients are then treated with folic or folinic acid they will respond hwmatologically to this treatment but the serum B12 concentrations will gradually fall once more to low levels. This is in contrast to the results of treatment in patients with pernicious anemia in whom the marrow does not again become megaloblastic until the serum B12 level has fallen below the normal range.
Conclusions
We have briefly discussed some of the ways in which the assay of the B12 concentrations of serum may be of value in the investigation of the megaloblastic anemias.
The method has proved particularly valuable for demonstrating B12 deficiency in patients who have little or no hmmatological evidence of such deficiency. In such patients serum B12 concentrations of about 100 p4Lg./ml. or less indicate B12 deficiency. The method is useful for confirming the diagnosis of subacute combined degeneration of the cord in patients without anemia; in these patients the serum B12 concentrations are always very low.
Because the assay of the concentration of B12 in the serum is more sensitive for demonstrating B12 deficiency than ordinary hematological techniques it is valuable for determining the exact incidence of B12 deficiency in various special populations, e.g. in patients following gastrectomy, in vegetarians or in the relatives of patients known to be suffering from pernicious anemia. By studying such groups it should be possible to discover how long an interval may elapse before demonstrable anemia develops after the serum B12 level has fallen below the normal range. In some patients with pernicious anemia we have found the serum B12 level to be low but the blood picture normal or almost normal for periods of at least one to two years. It is also a most convenient method of determining the specific deficiency in patients with florid megaloblastic anemia and used in conjunction with the hxematological response to treatment it can help to prove a double deficiency of B12 and folic acid. MOLLIN, D. L., Cox, E. V., and UNGLEY, C. C. (1954) Blood, 9, 473. [March 9, 1954] Pharmacology and Experimental Medicine [Abridged] PRESIDENT'S ADDRESS
IT has become commonplace to refer to the enormous developments in Therapeutics. As judged by the rather crude standard of the number of new drugs introduced, there have been as many new ones since 1900 as in the whole of the previous history of the subject. Whereas fifty years ago improvements in treatment were dependent only on clinical observation of patients, recently the great majority, but not all, of the advances have come in the first instance from the results of animal experiment. The initiative has rested to a great extent with the pharmacologist and the chemist whose responsibility it had become to suggest substances for clinical trial. Of course it only too often happens that many substances which are suggested do not fulfil the hopes originally placed in them and the trial and final assessment must always be the result of years of clinical work. These great developments are by no means all due to animal experiment and the new knowledge has so awakened interest in therapeutics that a great number of discoveries are now being made during the treatment of patients themselves. Thus, the effect of cortisone and ACTH in rheumatoid arthritis would never have been predicted but for the work on patients. This field of clinical experiment is developing fast and may lead to as rich a harvest in therapeutic discovery in the future as animal experiment has done in the immediate past.
The work of the pharmacological departments of large drug firms has done much for therapeutics. They are not troubled to the same extent with the important question of the cost of research, but they are often unwilling to grapple with problems which may require much time before any result can be expected, and the "sponsored project" to produce a new antihistamine or a new antimalarial sometimes leads to work being directed to fields where there are often already a number of available remedies more than to the difficult problems where no advances as yet have been made. However difficult and unpromising these problems may appear it is important that work be directed to their solution, for the treatment of diabetes appeared unpromising before Banting and there was very little indication of the possibility of chemotherapeutic substances for bacterial infection before the sulphonamides.
Discoveries have usually only been made possible by years of hard work but in many important advances a lucky chance and the ability to make use of it have also been very important. The use of dyes in chemotherapy has been popular since the time of Ehrlich, and Domagk was experimenting with Prontosil because the introduction of a sulphonamide group into a dye had been found to increase its fastness in staining wool fibre. As in many pharmacological discoveries the reason which prompted the choice of the substance had little to do with the way in which it was finally shown to act.
THERAPY OF INFECIONs
The therapy of tuberculosis is a problem which presents many features different from those encountered in the acute infections, and there is a striking lack of correlation between the results of in vitro and in vivo tests due presumably to the inaccessibility of the organism in the infected host. The sulphone, dapsone, was the first substance to produce a significant effect in experimental infections and later streptomycin proved very much more effective. A notable advance has been made by the use of two antituberculous agents together; although one may be much less potent than the other, the use of the two together greatly delays the development of resistance to either.
The sulphone, dapsone, was first combined with streptomycin, then PAS and streptomycin were found much more satisfactory, and now it seems possible that streptomycin, with its many disadvantages, may be entirely dispensed with, and that PAS and isoniazid may prove as effective as any other combination. Organisms quickly become resistant when either agent is used alone but when the two are combined the development of the resistance is very considerably delayed.
It is very interesting that these principles have become more apparent as the result of clinical trials in patients when the organism is in contact with antituberculous agent for a much longer period than in animal experiments, which last only a few weeks. It would be of interest to know whether three agents together might be significantly better than two. It is very possible that further research may show more potent agents. The latest addition to this field, pyrazinamide, when combined with isoniazid was found to get rid of all the tubercle bacilli in mouse spleens more readily than any combination previously tried, and results on patients have been equally promising except for occasional appearances of liver damage.
The treatment of leprosy is a problem somewhat clearly associated with that of tuberculosis. The sulphone, dapsone, was soon found to be effective, but both streptomycin and isoniazid when given alone do not have an appreciable effect. Although dapsone and its derivative, solapsone, have proved far more reliable than any other means of treatment so far employed, the response is extremely slow and in a series of cases examined six months after the inception of treatment and compared with an equal number cf controls, only 30% more of the treated cases were noted as improved in comparison with the controls. In the assessment of new drugs it is not possible to use in vitro methods or to test on infected animals. The clinical test is so slow that eighteen months elapses before a result is available, also large quantities of material are required for the trials. There is so much clinical material available that it is regrettable that more trials of new drugs are not being carried out, and, in particular, it would seem worth trying combinations which have proved so effective in tuberculosis.
The many substances which are now available for the treatment of bacterial diseases, a development started by the discovery of the sulphonamides, have rendered possible the treatment of all infectious conditions except those with pathogenic fungi at one end of the scale, and those with the smaller viruses at the other end. Amongst the pathogenic fungi actinomycosis responds to penicillin, and much active work is in progress to find agents which will deal with the others. The large viruses, lymphogranuloma and psittacosis, respond to the same general lines of chemotherapy as do bacteria. The small viruses on the other hand seem to present an entirely different problem. Both influenza and poliomyelitis have so far completely eluded all attempts at chemotherapy.
The problem of the chemotherapy of virus infections is very much more difficult than that of bacterial infections. The virus is a more intimate part of the cell of the host. The rate of multiplication of the virus is far greater than that of the bacteria and our difficulty is considerably increased by our inability to grow the virus apart from the animal tissue. The introduction of tissue culture work may prove a considerable help in this matter, but so far no very significant advances have been made.
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A number of very different substances are found to have a possible small influence on the rate of multiplication of the poliomyelitis virus in the mouse, but none of these have been sufficiently active to suggest any line of further investigation.
So far it appears that there is no suggestion of the possibility of influencing the virus once the infection is established although there are indications of the possibility of the inhibition of one virus by another and of the inhibition of some neurotropic virus infections by the use of dyes, notably trypan red. These effects have, however, not been of such a character as to make possible a therapeutic test in man.
The only possible means of protecting against the infections with the smaller viruses at the moment is by active immunization, and it appears that the field of the chemotherapy of viruses is one which may require a great deal of work before any significant advance can be achieved.
THERAPY OF CANCER
The treatment of cancer still presents a most difficult and unpromising problem for the pharmacologist. This is an important question now, and is likely to become a much more urgent one in the future owing to the successful therapy of nearly all infectious conditions. The main attempts at treatment other than by surgery or by irradiation have been by hormones and by excision of endocrine glands, by substances which inhibit cell division, such as nitrogen mustard, and by substances which may interfere with the utilization of metabolites such as aminopterin, and 6-mercaptopurine. Nitrogen mustard, or mustine, has been found useful in Hodgkin's disease and its action appears to depend on the formation of a cross linkage between the chromosomes of the dividing cells. Other derivatives which have been developed from it are T.E.M., also used in Hodgkin's disease, Myleran used for chronic myelogenous leukemia and bischloroethylaminophenyl butyric acid for chronic lymphatic leukemia. In the case of all the substances resistance to the drug soon appears. This development of resistance is a phenomenon which is also marked in the therapy of tuberculosis, and in the latter case the most useful approach to the problem has been through the use of two antituberculous agents together, presumably the one can deal with the bacteria which have become resistant to the other. It would be interesting to determine whether any effect of the same character could be observed in the treatment of cancer. Although the pathological conditions are absolutely different, the rapidly dividing cancer cell may possibly be induced to behave in a manner analogous with that of the tubercle bacillus in this respect. In connexion with this it would be of particular interest if another drug in addition to nitrogen mustard could be found to influence Hodgkin's disease. Possibly if such were found a much better effect might be produced than that found with nitrogen mustard alone. There appears to be some evidence for the advantage of combined treatment in acute leukvmias and the use of aminopterin and 6-mercaptopurine together in cases of acute leukemia has given a better result than either agent alone.
Hormone treatment of breast and prostate tumours is common practice and ovariectomy was first tried for inoperable breast tumours by Sir George Beatson in 1869, but it did not give consistent effects. It has been known for a long time that in pathological conditions the adrenals can produce steroids with cestrogenic and androgenic functions and recently Huggins appears to have made a considerable advance in the treatment of inoperable differentiated breast tumours by performing bilateral adrenalectomy in patients without ovarian function; and maintaining them by injections of DOCA and cortisone.
The development of resistance to nitrogen mustard and similar substances is an interesting point of study with transplantable tumours like the Walker rat tumour where resistance once it is established is maintained during any number of further transplantations. Such research may eventually show some indication for improving the effect of the drug in Hodgkin's disease.
GENERAL
One of the aspects of pharmacology to which a great deal of attention is now being directed is the production of inhibitory drugs. These may be either drugs which inhibit the action of a substance occurring in the body, like adrenaline, histamine or acetylcholine, or they may be drugs which are thought to act by so-called substrate competition and prevent the access to an invading organism of some necessary metabolite, as in the case of sulphanilamide and para-aminobenzoic acid. Inhibitory drugs sometimes have a structure very similar to that of the substance whose action they are inhibiting, thus nalorphine has a structure identical to that of morphine except for the substitution of the methyl by the allyl group; on the other hand sometimes, as in the case of the antihistamines, although the original drugs closely resembled the substance to be inhibited, further modifications have almost completely obliterated the resemblance. In the production of inhibitory substances to known drugs, chemical modifications of the molecule as by the introduction of an unsaturated group in the case of nalorphine, or by alteration in the distance between polar groups as in the methonium series, does give a guide to the design of the inhibitor, at any rate in the initial stages of the work. In chemo-therapy such theoretical considerations have not led to practically useful results, the explanation of the action, if it is discovered at all, usually only follows at a long interval after the drug is found.
Chemotherapy has remained a science where a number of substances must be tried in the whole animal, and there are comparatively few rules to indicate to the experimenter the best road to follow. The one exception to this is the finding of Hawking and MacIlwain that pantoyltaurin would prevent the assimilation of pantoylthenate by hwemolytic streptococci and thus act as a chemotherapeutic agent in infections of the rat but not in the mouse. This work has no practical usefulness at present, but may well be a pointer as to the design of experiments for the future. It seems that we must wait for further considerable developments in biochemistry before chemotherapy can become in any way an exact science.
Several discoveries in therapeutics have come from observations on patients alone. Thus the action of digitalis on the heart in auricular fibrillation and later that of quinidine, would never have been found but for clinical observation. In the case of liquid extract of ergot, the pharmacologists were sceptical of the action on the uterus observed by gynecologists, as laboratory experiments gave no indication of its activity, and it contained no ergotoxine or ergotamine. The discovery of ergometrine in -this liquid extract depended entirely on the observations in the human patient, and this finding was made by a clinician so sure of his observations on his patients that he continued his work in spite of some discouragement from those who had worked only on animals.
The discovery of the action of cortisone and of ACTH in rheumatoid arthritis was suggested by the observation of the remissions of the condition in pregnancy and jaundice, conditions where the suprarenal cortex was known to be more active than usual. Although this discovery has stimulated a great deal of experimental work on animals, the initial step was entirely due to clinical observation.
Recently the action of phenylbutazone in rheumatoid conditions was observed owing to the substance being used as a solvent for amidopyrine.
It would seem that an ever-increasing number of discoveries may well be made by observations on patients in the future, particularly as clinicians become more interested in the action of the drugs they use. In so many conditions it is not possible to imitate the disease on the experimental animal, and it is here that clinical pharmacology is of paramount importance. There is certainly need in pharmacology to tackle problems which are of use to clinicians, and probably an even greater need for clinicians to cultivate an interest in pharmacology and to observe and investigate any unusual effects seen in their patients.
